Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akebia Therapeutics (AKBA – Research Report) and Integra Lifesciences (IART – Research Report).
Integra Lifesciences (IART)
In a report released today, Ryan Zimmerman from BTIG reiterated a Hold rating on Integra Lifesciences. The company’s shares closed last Wednesday at $35.17.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Integra Lifesciences with a $47.50 average price target, representing a 35.6% upside. In a report issued on October 13, Truist Financial also maintained a Hold rating on the stock with a $41.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AKBA:
